Additionally, the SGLT2 inhibitor DAPA demonstrated a dose- and time-dependent inhibition of cell growth, with greater sensitivity observed in RCC cells than in HK-2 cells. The gene discussed is SLC5A2; the disease is renal cell carcinoma.